Preferred Label : Larotrectinib Sulfate;
NCIt synonyms : (3S)-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide;sulfuric
acid; LOXO-101 Sulfate; ARRY 470 Sulfate; LOXO 101 Sulfate; 1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-Difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-,
(3S)-, Sulfate (1:1);
NCIt definition : The sulfate salt form of larotrectinib, an orally available, tropomyosin receptor
kinase (Trk) inhibitor, with potential antineoplastic activity. Upon administration,
larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk
activation, which results in both the induction of cellular apoptosis and the inhibition
of cell growth in tumors that overexpress Trk. Trk, a receptor tyrosine kinase activated
by neurotrophins, is mutated in a variety of cancer cell types and plays an important
role in tumor cell growth and survival.;
UNII : RDF76R62ID;
InChIKey : PXHANKVTFWSDSG-QLOBERJESA-N;
CAS number : 1223405-08-0; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1223405-08-0
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Drug name : Vitrakvi;
NCI Metathesaurus CUI : CL935988;
Origin ID : C156895;
UMLS CUI : C4740883;
See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_free_acid_or_base_form
- has_target
- is_salt_form_of
